Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) have been given a consensus rating of “Moderate Buy” by the seven research firms that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation, three have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $11.50.

A number of research analysts have recently weighed in on KPTI shares. Piper Sandler reduced their target price on shares of Karyopharm Therapeutics to $7.00 and set an “overweight” rating for the company in a research report on Friday, July 31st. Cantor Fitzgerald reiterated an “overweight” rating on shares of Karyopharm Therapeutics in a research note on Tuesday, June 9th. Royal Bank Of Canada reissued an “outperform” rating and set a $16.00 price objective on shares of Karyopharm Therapeutics in a report on Tuesday, July 21st. Robert W. Baird cut Karyopharm Therapeutics from an “outperform” rating to a “neutral” rating and set a $3.00 price target on the stock. in a research report on Friday, July 31st. Finally, HC Wainwright lowered Karyopharm Therapeutics from a “buy” rating to a “negative” rating in a report on Friday, July 31st.

Institutional Investors Weigh In On Karyopharm Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Royal Bank of Canada grew its holdings in Karyopharm Therapeutics by 4.1% during the 1st quarter. Royal Bank of Canada now owns 60,399 shares of the company’s stock valued at $336,000 after buying an additional 2,399 shares in the last quarter. Corient Private Wealth LLC bought a new stake in shares of Karyopharm Therapeutics during the fourth quarter valued at about $74,000. Baird Financial Group Inc. purchased a new stake in shares of Karyopharm Therapeutics in the second quarter worth about $45,000. Hsbc Holdings PLC purchased a new stake in shares of Karyopharm Therapeutics in the first quarter worth about $66,000. Finally, Headlands Technologies LLC bought a new position in shares of Karyopharm Therapeutics in the second quarter valued at approximately $118,000. Institutional investors own 66.44% of the company’s stock.

Karyopharm Therapeutics Stock Performance

Shares of NASDAQ:KPTI opened at $1.87 on Monday. The company has a market capitalization of $42.41 million, a P/E ratio of -0.14 and a beta of 0.90. The company’s 50-day moving average is $6.03 and its 200 day moving average is $7.54. Karyopharm Therapeutics has a fifty-two week low of $1.79 and a fifty-two week high of $10.99.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($2.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.37) by ($0.95). The company had revenue of $33.43 million for the quarter, compared to analyst estimates of $32.19 million. As a group, research analysts predict that Karyopharm Therapeutics will post -4.7 earnings per share for the current year.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.